John McBride has been appointed chief financial officer of Cadent Therapeutics. He was most recently the CFO of Syntimmune, which was acquired by Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) last year. Cambridge, MA-based Cadent raised $40 million in financing last November to advance its lead drug into Phase 2 testing for two movement disorders.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
